Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Public ClinicalTrials.gov record NCT01624285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation
Study identification
- NCT ID
- NCT01624285
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Interventions
- sorafenib tosylate Drug
- placebo Other
- laboratory biomarker analysis Other
Drug · Other
Eligibility (public fields only)
- Age range
- 19 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2012 (Actual)
- Primary completion
- Feb 2023 (Actual)
- Completion
- Feb 2023 (Actual)
- Last update posted
- Dec 14, 2023
2012 – 2023
United States locations
- U.S. sites
- 21
- U.S. states
- 19
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294-0007 | — |
| Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
| University of Colorado | Denver | Colorado | 80217-3364 | — |
| Mount Sinai Hospital | Hartford | Connecticut | 06112 | — |
| Lombardi Comprehensive Cancer Center at Georgetown University | Washington D.C. | District of Columbia | 20057 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287-8936 | — |
| Lahey Clinic Medical Center | Burlington | Massachusetts | 01805 | — |
| University of Michigan University Hospital | Ann Arbor | Michigan | 48109 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-7830 | — |
| University of Pennsylvania Health System | Cherry Hill | New Jersey | 08034 | — |
| New York University Langone Medical Center | New York | New York | 10016 | — |
| New York Presbyterian-The University Hospital of Columbia and Cornell | New York | New York | 10065 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Integris-Baptist Medical | Oklahoma City | Oklahoma | 73112 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| The Methodist Hospital Research Institute | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01624285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 14, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01624285 live on ClinicalTrials.gov.